Around 2.8 million Americans suffer from treatment-resistant depression, and though research has shown that IV ketamine can significantly improve their quality of life, these ketamine treatments are expensive, and access to them is limited. Early in the covid-19 pandemic, the Drug Enforcement Agency loosened…